João Paulo Maia-de-Oliveira
Psychiatrist and Assistant Professor of Psychiatry at the Federal University of Rio Grande do Norte
Data updated
Research Footprint
João Paulo Maia-de-Oliveira appears in 6 tracked papers (2015–2020), most studied alongside Ayahuasca and Placebo, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (814 citations).
Frequent co-authors: Draulio Araújo, Jamie Hallak and Fernanda Palhano-Fontes.
Background & Research
João Paulo Maia de Oliveira graduated in medicine from the Federal University of Rio Grande do Norte and completed psychiatric training and graduate studies in mental health/psychiatry at the University of São Paulo. Sources describe him as a psychiatrist and an assistant professor of psychiatry at UFRN, with research interests spanning schizophrenia, depression, and translational research. He appears as a coauthor on multiple influential ayahuasca trials and related biomarker studies.
Key Impact
He is a Brazilian psychiatrist and clinical researcher best known for co-authoring multiple landmark clinical studies on ayahuasca's rapid antidepressant, anti-suicidal, and biomarker effects.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations João Paulo Maia-de-Oliveira is associated with.
Federal University of Rio Grande do Norte, Brain Institute
The Brain Institute at the Federal University of Rio Grande do Norte is a Brazilian academic neuroscience center conducting translational research relevant to mental health and psychedelic science collaborations.
View stakeholder →Federal University of Rio Grande do Norte (UFRN)
Federal University of Rio Grande do Norte is a public research university in Brazil with active neuroscience and mental health research programmes, including work linked to psychedelic science through affiliated institutes.
View stakeholder →